The total number of records retrieved from this search are 31. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_582	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89(10 μM) for 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.001 PFU/cell	In-vitro result86% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_583	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNon toxic to human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.001 PFU/cell	In-vitro result100% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_584	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89(10 μM) for 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.01 PFU/cell	In-vitro result80% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_585	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNon toxic to human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.01 PFU/cell	In-vitro result100% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_586	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89(10 μM) for 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.1 PFU/cell	In-vitro result70% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_587	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNon toxic to human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.1 PFU/cell	In-vitro result100% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_588	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89(10 μM) for 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration1 PFU/cell	In-vitro result38% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_589	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNon toxic to human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration1 PFU/cell	In-vitro result90% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_590	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89(10 μM) for 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result25% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_591	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNon toxic to human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result80% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_600	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with ESI-09 and with H89(10 μM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 PFU/cell	In-vitro result75% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedESI-09 abrogates the activities of Caspase-3/9/8 induced by H89/M1 combination treatment.	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_601	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with ESI-09	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic ductal adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 PFU/cell	In-vitro result82% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedESI-09 abrogates the activities of Caspase-3/9/8 induced by H89/M1 combination treatment.	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_2270	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineCapan-1	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2284	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineCapan-1	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2298	Virus nameVesicular stomatitis virus	Virus strainVSV-p1-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of P gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineCapan-1	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2312	Virus nameVesicular stomatitis virus	Virus strainSev-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineCapan-1	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2326	Virus nameVesicular stomatitis virus	Virus strainRSV-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineCapan-1	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2340	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineCapan-1	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result5% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2354	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineCapan-1	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result2% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2368	Virus nameVesicular stomatitis virus	Virus strainVSV-p1-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of P gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineCapan-1	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result2% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2382	Virus nameVesicular stomatitis virus	Virus strainSev-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineCapan-1	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result70% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2396	Virus nameVesicular stomatitis virus	Virus strainRSV-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineCapan-1	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_4315	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreas adenocarcinoma	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result85.1 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4353	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4354	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4355	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4356	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4357	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4361	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with dbcAMP 100 micromoalr	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4362	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with dbcAMP 200 micromoalr	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result60% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4363	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with dbcAMP 400 micromoalr	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineCapan-1	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347